About Us

At Iterative Scopes, we are using scalable technology to eliminate disparities in healthcare outcomes.

​

Iterative Scopes is a pioneer in the application of artificial intelligence-based precision medicine to gastroenterology with the aim of establishing a new standard of care for the detection, and ultimately, treatment of gastrointestinal (GI) diseases. Its powerful, proprietary artificial intelligence and computer vision technologies are designed with the goal of improving the accuracy and consistency of endoscopy readings.

For a variety of reasons, GI practitioners have seen fewer advancements from precision medicine technologies compared to those who treat other serious illnesses such as oncologists and infectious diseases specialists. Current endoscopic procedures can be fairly subjective, leading to wide variations in interpretation and treatment decisions, and delays in clinical trials.

​

The company's computational/AI-driven software targets the following applications:

​

• The AI Recruitment service is designed to help clinical research sites and pharmaceutical sponsors accelerate their IBD clinical trials through a combination of cutting-edge proprietary AI-driven algorithms and computer vision advances.

​

• SKOUT™ , the company’s automated polyp detection tool, is an artificial intelligence (AI)-driven medical device that aims to improve and standardize insights from endoscopic videos. It can potentially assist gastroenterologists in identifying precancerous lesions to improve their clinical decision making. Data from a clinical trial using SKOUT was submitted to the FDA in a 510(k) filing for review in November 2021. SKOUT is not available for sale in the United States. It has CE mark certification in the European Union under the MDD (Directive 93/42/EEC).

​​​

​

The company has achieved robust milestones, including a network of partnerships with leading cross-industry GI stakeholders, the recruitment of top talent to its leadership team and scientific and industry advisory boards, and the backing of top tier financial institutions. Fortified by a founder CEO with expertise in healthcare, and a leadership team with extensive experience in GI disease management, drug development, and the application of data science innovations to clinical care, the company was spun out of MIT in 2017, and is based in Cambridge, Massachusetts.

​

In December 2021, Iterative Scopes closed a $150 million Series B financing round and has raised $182 million in investor funding since 2021. 

123

4